IDDF2022-ABS-0155 Global genome study of helicobacter pylori phage opens new paradigm on their worldwide distribution, genetic feature, and impacts on antimicrobial resistance, disease advancement, and achievement for phage-based therapy

BackgroundAlthough the study of bacteriophages has recently increased, the knowledge about phages in Helicobacter pylori remains limited. We conducted a global-scale study to understand their worldwide distribution, genetic feature, and impacts on antimicrobial resistance (AMR) along with clinical disease profiles. We also tried to find a new valuable candidate for phage-based therapy.MethodsWe performed in-depth genome analysis through 1979 clinical H.pylori, retrieved from 68 countries worldwide. Phage identification and further investigation were identified using well-established tools. We analyzed their clinical impact using 552 antibiogram data of six antibiotics and 258 clinical-histological data. Both data were retrieved from H.pylori-infected patients across multi nations.ResultsWe successfully identified 1075 phage elements and 165 intact phages. The intact phages mostly tended to become virulent (58.18;96/165) than remain temperate (41.81;69/165). Most temperate phages were active (62.32;43/69). We found 16 novel bacteriophages, including two novel-phage species. We demonstrated for the first time that their distribution was correlated with geographical and ancestral populations, with some initially reported from non-Helicobacter phage (IDDF2022-ABS-0155 Figure 1. Phage distribution and novel bacteriophage species and strains A phage distribution based on the geographical area B phage distribution based on the H pylori ancestral popul). Helicobacter phage had different GC content than non-Helicobacter phage. The GC content variation of Helicobacter phage was correlated with the GC content of the H.pylori chromosome (r=0.525; p